Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BIC Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT02397694
View directory record Official record
Conditions
HIV-1 Infection
Interventions
BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Phase 4 Interventional Results available

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

NCT04530630
View directory record Official record
Conditions
HIV Infections, Renal Transplant Rejection
Interventions
BIC/F/TAF 50Mg-200Mg-25Mg Tablet
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

NCT04143594
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

NCT06532656
View directory record Official record
Conditions
HIV-1-infection
Interventions
Lenacapavir, BIC/LEN FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

NCT04233879
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Recruiting Not applicable Interventional

Suicide Prevention After Community Care Discharge

NCT06596044
View directory record Official record
Conditions
Suicide Prevention
Interventions
VA BIC, Standard Care
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Phase 4 Interventional Results available

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

NCT04039217
View directory record Official record
Conditions
ART, HIV
Interventions
Biktarvy
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 2, 2026, 1:59 AM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Not applicable Interventional Results available

Suicide Prevention Study of VA-BIC in the Veteran Population

NCT04446468
View directory record Official record
Conditions
Suicide Prevention
Interventions
PEACE, Standard Psychiatric Hospital Discharge Care
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-College Bystander Efficacy Evaluation

NCT02659423
View directory record Official record
Conditions
Sexual Violence
Interventions
BIC 1, BIC 2, BIC 3
Behavioral
Lead sponsor
Ann Coker
Other
Eligibility
18 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

NCT02881320
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
1 Month to 17 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Affordable Mobile Robots for the Elderly

NCT02807506
View directory record Official record
Conditions
Aging
Interventions
Mobile Service Robot, Survey
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Not applicable Interventional

Dynamic Deconstructive Psychotherapy Versus Brief Intervention and Contact for Suicidal Adolescents and Young Adults

NCT05988489
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Dynamic Deconstructive Psychotherapy (DDP), Brief Intervention and Contact (BIC)
Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
14 Years to 40 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

NCT01098266
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
NGR-hTNF plus Best Investigator's Choice (BIC), Placebo plus Best Investigator's Choice (BIC)
Drug
Lead sponsor
AGC Biologics S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Corona, California • Duarte, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 2, 2026, 1:59 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Doravirine and Weight Gain in Antiretroviral Naive

NCT05457530
View directory record Official record
Conditions
Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions
DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
Drug · Combination Product
Lead sponsor
Prism Health North Texas
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tennessee Youth Prepared for Success

NCT06001892
View directory record Official record
Conditions
Adolescent Behavior, Adolescent Problem Behavior, Risk Reduction
Interventions
Tennessee Youth Prepared for Success
Behavioral
Lead sponsor
Centerstone Research Institute
Other
Eligibility
14 Years to 19 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Not applicable Interventional

Acute Recording of Stereotyped High-Frequency Oscillations

NCT05439655
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Interchange System
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Completed No phase listed Observational

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

NCT06393387
View directory record Official record
Conditions
Hiv, HIV-1-infection, HIV Infections
Interventions
DTG/3TC versus BIC/F/TAF
Drug
Lead sponsor
Midway Specialty Care Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Not applicable Interventional

Impact of Rapid ART Initiation on Retention in Care in the Southern US

NCT04266938
View directory record Official record
Conditions
HIV-1-infection
Interventions
Rapid start of antiretrovirals, Retrospective analysis, Non- RAPID start
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 2, 2026, 1:59 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

NCT04223791
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 2, 2026, 1:59 AM EDT
Completed Not applicable Interventional

Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer

NCT01876238
View directory record Official record
Conditions
Advanced Breast Cancer, Stage 4 Breast Cancer, Recurrent Breast Cancer
Interventions
T-PAT, Surveys
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 2, 2026, 1:59 AM EDT